Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
94,000
+1,200 (1.29%)
Apr 29, 2026, 9:10 AM KST
142.58%
Market Cap 2.82T
Revenue (ttm) 7.91B
Net Income (ttm) -34.93B
Shares Out 30.39M
EPS (ttm) -1,160.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,589
Average Volume 146,696
Open 93,600
Previous Close 92,800
Day's Range 92,100 - 94,200
52-Week Range 35,500 - 179,900
Beta 1.50
RSI 48.71
Earnings Date Apr 3, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2025, Mezzion Pharma's revenue was 7.91 billion, a decrease of -8.15% compared to the previous year's 8.61 billion. Losses were -34.93 billion, 79.3% more than in 2024.

Financial Statements

News

There is no news available yet.